144 related articles for article (PubMed ID: 9873609)
1. NGB 2904 and NGB 2849: two highly selective dopamine D3 receptor antagonists.
Yuan J; Chen X; Brodbeck R; Primus R; Braun J; Wasley JW; Thurkauf A
Bioorg Med Chem Lett; 1998 Oct; 8(19):2715-8. PubMed ID: 9873609
[TBL] [Abstract][Full Text] [Related]
2. Effects of two novel D3-selective compounds, NGB 2904 [N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-9H-fluorene-2-carboxamide] and CJB 090 [N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzamide], on the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys.
Martelle JL; Claytor R; Ross JT; Reboussin BA; Newman AH; Nader MA
J Pharmacol Exp Ther; 2007 May; 321(2):573-82. PubMed ID: 17272677
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological actions of NGB 2904, a selective dopamine D3 receptor antagonist, in animal models of drug addiction.
Xi ZX; Gardner EL
CNS Drug Rev; 2007; 13(2):240-59. PubMed ID: 17627675
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of [(2,3-dichlorophenyl)piperazin-1-yl]alkylfluorenylcarboxamides as novel ligands selective for the dopamine D3 receptor subtype.
Robarge MJ; Husbands SM; Kieltyka A; Brodbeck R; Thurkauf A; Newman AH
J Med Chem; 2001 Sep; 44(19):3175-86. PubMed ID: 11543687
[TBL] [Abstract][Full Text] [Related]
5. N-(4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl, butenyl and butynyl)arylcarboxamides as novel dopamine D(3) receptor antagonists.
Newman AH; Cao J; Bennett CJ; Robarge MJ; Freeman RA; Luedtke RR
Bioorg Med Chem Lett; 2003 Jul; 13(13):2179-83. PubMed ID: 12798330
[TBL] [Abstract][Full Text] [Related]
6. Novel benzopyrano[3,4-c]pyrrole derivatives as potent and selective dopamine D3 receptor antagonist.
Dubuffet T; Newman-Tancredi A; Cussac D; Audinot V; Loutz A; Millan MJ; Lavielle G
Bioorg Med Chem Lett; 1999 Jul; 9(14):2059-64. PubMed ID: 10450981
[TBL] [Abstract][Full Text] [Related]
7. The dopamine D3 receptor partial agonist, BP 897, is an antagonist at human dopamine D3 receptors and at rat somatodendritic dopamine D3 receptors.
Wicke K; Garcia-Ladona J
Eur J Pharmacol; 2001 Jul; 424(2):85-90. PubMed ID: 11476753
[TBL] [Abstract][Full Text] [Related]
8. The dopamine D3 receptor antagonist NGB 2904 increases spontaneous and amphetamine-stimulated locomotion.
Pritchard LM; Newman AH; McNamara RK; Logue AD; Taylor B; Welge JA; Xu M; Zhang J; Richtand NM
Pharmacol Biochem Behav; 2007 Apr; 86(4):718-26. PubMed ID: 17408730
[TBL] [Abstract][Full Text] [Related]
9. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH
J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168
[TBL] [Abstract][Full Text] [Related]
10. 6-(4-Benzylpiperazin-1-yl)benzodioxanes as selective ligands at cloned primate dopamine D(4) receptors.
Hodgetts KJ; Kieltyka A; Brodbeck R; Tran JN; Wasley JW; Thurkauf A
Bioorg Med Chem; 2001 Dec; 9(12):3207-13. PubMed ID: 11711296
[TBL] [Abstract][Full Text] [Related]
11. Interactive SAR studies: rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists.
Bettinetti L; Schlotter K; Hübner H; Gmeiner P
J Med Chem; 2002 Oct; 45(21):4594-7. PubMed ID: 12361386
[TBL] [Abstract][Full Text] [Related]
12. (S)-(-)-4-[4-[2-(isochroman-1-yl)ethyl]-piperazin-1-yl] benzenesulfonamide, a selective dopamine D4 antagonist.
TenBrink RE; Bergh CL; Duncan JN; Harris DW; Huff RM; Lahti RA; Lawson CF; Lutzke BS; Martin IJ; Rees SA; Schlachter SK; Sih JC; Smith MW
J Med Chem; 1996 Jun; 39(13):2435-7. PubMed ID: 8691438
[No Abstract] [Full Text] [Related]
13. Substituted [(4-phenylpiperazinyl)-methyl]benzamides: selective dopamine D4 agonists.
Glase SA; Akunne HC; Georgic LM; Heffner TG; MacKenzie RG; Manley PJ; Pugsley TA; Wise LD
J Med Chem; 1997 Jun; 40(12):1771-2. PubMed ID: 9191952
[No Abstract] [Full Text] [Related]
14. In vitro pharmacological profile of YM-43611, a novel D2-like receptor antagonist with high affinity and selectivity for dopamine D3 and D4 receptors.
Hidaka K; Tada S; Matsumoto M; Ohmori J; Tasaki Y; Nomura T; Usuda S; Yamaguchi T
Br J Pharmacol; 1996 Apr; 117(8):1625-32. PubMed ID: 8732269
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and structure-activity relationship studies of a series of [4-(4-carboxamidobutyl)]-1-arylpiperazines: insights into structural features contributing to dopamine D3 versus D2 receptor subtype selectivity.
Ananthan S; Saini SK; Zhou G; Hobrath JV; Padmalayam I; Zhai L; Bostwick JR; Antonio T; Reith ME; McDowell S; Cho E; McAleer L; Taylor M; Luedtke RR
J Med Chem; 2014 Aug; 57(16):7042-60. PubMed ID: 25126833
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and characterization of selective dopamine D₂ receptor ligands using aripiprazole as the lead compound.
Vangveravong S; Zhang Z; Taylor M; Bearden M; Xu J; Cui J; Wang W; Luedtke RR; Mach RH
Bioorg Med Chem; 2011 Jun; 19(11):3502-11. PubMed ID: 21536445
[TBL] [Abstract][Full Text] [Related]
17. Reduced expression of haloperidol conditioned catalepsy in rats by the dopamine D3 receptor antagonists nafadotride and NGB 2904.
Banasikowski TJ; Beninger RJ
Eur Neuropsychopharmacol; 2012 Oct; 22(10):761-8. PubMed ID: 22410316
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of novel 2,3-dihydro-1H-isoindoles with high affinity and selectivity for the dopamine D3 receptor.
Austin NE; Avenell KY; Boyfield I; Branch CL; Hadley MS; Jeffrey P; Johnson CN; Macdonald GJ; Nash DJ; Riley GJ; Smith AB; Stemp G; Thewlis KM; Vong AK; Wood MD
Bioorg Med Chem Lett; 2001 Mar; 11(5):685-8. PubMed ID: 11266169
[TBL] [Abstract][Full Text] [Related]
19. Examining the Effects of Sodium Ions on the Binding of Antagonists to Dopamine D2 and D3 Receptors.
Newton CL; Wood MD; Strange PG
PLoS One; 2016; 11(7):e0158808. PubMed ID: 27379794
[TBL] [Abstract][Full Text] [Related]
20. Dopamine D3 receptor antagonism contributes to blonanserin-induced cortical dopamine and acetylcholine efflux and cognitive improvement.
Huang M; Kwon S; Oyamada Y; Rajagopal L; Miyauchi M; Meltzer HY
Pharmacol Biochem Behav; 2015 Nov; 138():49-57. PubMed ID: 26383990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
